Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473616 · ClinicalTrials.gov registry record · Phase 1
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00473616 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 60 participants.
The verdict
NCT00473616, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.
Interventions
- DRUG Irinotecan
- DRUG AZD7762
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473616
The ClinicalTrials.gov registry entry for NCT00473616 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT00473616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00473616 about?
NCT00473616 is a clinical study titled "Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan". This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by...
What is the current status of trial NCT00473616?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00473616?
The interventions under investigation include: Irinotecan (DRUG), AZD7762 (DRUG).
Who is sponsoring clinical trial NCT00473616?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.